Table 3.
Treatment Group | Time, mo | No. of Patients/ Nodulesa | No. of Living Female Wormsb |
No. of Living Male Wormsb |
||||||
---|---|---|---|---|---|---|---|---|---|---|
Allc | With Wolbachiad |
Allc | With Wolbachiad |
|||||||
Many | Few | None | Many | Few | None | |||||
Doxycycline (6 wk) | 20 | 56/152 | 117 | 1 | 5 | 111 | 41 | 0 | 3 | 36 |
Placebo | 20 | 63/199 | 184 | 60 | 80 | 35 | 54 | 5 | 19 | 26 |
a Only evaluable patients/nodules are included; nodules with newly acquired worms only are subtracted.
b Newly acquired worms were subtracted (doxycycline, n = 8 females; placebo, n = 7 females).
c Although the number of all living worms is given to make the numbers consistent to the other tables, in 15 worms, it was not possible to distinguish if the worm had many, few, or no Wolbachia, due to too little worm material in the respective histological sections. Therefore, “All” is not always a summary of the 3 categories.
d Significant difference between the doxycycline and the placebo group regarding absence of Wolbachia (bP < .001 for female and male worms respectively, Fisher exact test).